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ARTICLE
Activation of STAT3 integrates common proﬁbrotic
pathways to promote ﬁbroblast activation and
tissue ﬁbrosis
Debomita Chakraborty1, Barbora Šumová1,2, Tatjana Mallano1, Chih-Wei Chen1, Alﬁya Distler1,
Christina Bergmann1, Ingo Ludolph3, Raymund E. Horch3, Kolja Gelse4, Andreas Ramming1, Oliver Distler5,
Georg Schett1, Ladislav Šenolt2 & Jörg H.W. Distler1
Signal transducer and activator of transcription 3 (STAT3) is phosphorylated by various
kinases, several of which have been implicated in aberrant ﬁbroblast activation in ﬁbrotic
diseases including systemic sclerosis (SSc). Here we show that proﬁbrotic signals converge
on STAT3 and that STAT3 may be an important molecular checkpoint for tissue ﬁbrosis.
STAT3 signaling is hyperactivated in SSc in a TGFβ-dependent manner. Expression proﬁling
and functional studies in vitro and in vivo demonstrate that STAT3 activation is mediated by
the combined action of JAK, SRC, c-ABL, and JNK kinases. STAT3-deﬁcient ﬁbroblasts are
less sensitive to the pro-ﬁbrotic effects of TGFβ. Fibroblast-speciﬁc knockout of STAT3, or its
pharmacological inhibition, ameliorate skin ﬁbrosis in experimental mouse models. STAT3
thus integrates several proﬁbrotic signals and might be a core mediator of ﬁbrosis.
Considering that several STAT3 inhibitors are currently tested in clinical trials, STAT3 might
be a candidate for molecular targeted therapies of SSc.
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F ibrotic diseases impose a major socioeconomic burden onmodern societies and have been estimated to account for45% of deaths in the developed world1. Their common
histopathological feature is an excessive accumulation of extra-
cellular matrix, which disrupts the physiological tissue archi-
tecture2. Tissue ﬁbrosis can occur after deﬁned stimuli with a
subsequent inﬂammatory response, but in many ﬁbrotic diseases,
no initiating trigger can be identiﬁed. These idiopathic ﬁbrotic
diseases can manifest on virtually every organ. A prototypical
systemic idiopathic ﬁbrotic disease is systemic sclerosis (SSc)3.
Failure of the affected organs is common in SSc and results in
high morbidity and mortality and no targeted therapies are yet
available for the treatment of ﬁbrosis in SSc2,3. Myoﬁbroblasts are
the principle source of extracellular matrix during physiologic
tissue repair as well as in ﬁbrotic diseases. However, while tissue
remodeling is tightly controlled in normal wound healing and is
turned off as soon as the damage is repaired, the ﬁbroblasts
escape this regulation1. Myoﬁbroblast differentiation may initially
be depended on proﬁbrotic cytokines, but with prolonged exter-
nal stimulation, myoﬁbroblasts become independent of external
stimuli and remain persistently activated in ﬁbrotic diseases.
Although the molecular mechanisms leading to aberrant acti-
vation of ﬁbroblasts are incompletely understood, transforming
growth factor-β (TGFβ) has been identiﬁed as a core pathway of
ﬁbrosis2–5. The levels of TGFβ are increased in ﬁbrotic diseases
and ﬁbroblasts display activation of TGFβ signaling with
increased transcription of TGFβ target genes4,6. Moreover, sti-
mulation of resting ﬁbroblasts with TGFβ induces an activated
myoﬁbroblast phenotype and a gene expression proﬁle in resting
ﬁbroblasts that is reminiscent of SSc ﬁbroblasts6,7. The key role of
TGFβ signaling in the pathogenesis of ﬁbrosis is further
demonstrated by the development of systemic ﬁbrosis in mice
with ﬁbroblast-speciﬁc overexpression of constitutively active
TGFβ receptor type I (TBRact)8. The effects of TGFβ are medi-
ated by a complex network of intracellular signaling events.
SMAD proteins that mediate canonical TGFβ signaling are con-
sidered as major intracellular mediators9. SMAD independent,
so-called non-canonical TGFβ pathways, such as mitogen acti-
vated involving the mitogen-activated protein kinases (MAPKs),
focal adhesion kinase (FAK), the tyrosine kinase c-ABL, and early
growth response 1 are also transducing in the pro-ﬁbrotic effects
of TGFβ10,11. However, inhibition of these downstream pathways
does not completely abrogate the pro-ﬁbrotic effects of
TGFβ12–14, indicating that additional pathways are important to
transduce the stimulatory effects of TGFβ. Identiﬁcation of these
novel downstream mediators of TGFβ might have translational
implications and may provide the basis for novel-targeted
therapies for ﬁbrotic diseases.
Signal transducer and activator of transcription 3 (STAT3) was
originally identiﬁed as an interleukin-6-activated transcription
factor and subsequently reported to also transduce signals from
several other stimuli including additional cytokines, hormones,
and growth factors15,16. Upon binding of these ligands to their
receptors, STAT3 is activated by phosphorylation at Tyr-705 in
the STAT3 transactivation domain. Phosphorylation of STAT3 at
Tyr-705 can be executed by kinases of the JAK and SRC families,
but also by other receptor- and non-receptor-associated tyrosine
kinases, such as JNK and c-ABL16–19. Phosphorylation at Tyr-705
is essentially required for STAT3 signaling as it allows STAT3 to
dimerize, translocate to the nucleus, and to modulate the tran-
scription of target genes and is thus commonly used to assess the
activation of STAT3 signaling. STAT3 regulates fundamental
cellular processes including inﬂammation, cell growth, prolifera-
tion, differentiation, migration, and apoptosis20. Given its broad
regulatory effects, it may not be surprising that deregulation of
STAT3 signaling has been linked to the pathogenesis of various
diseases. STAT3 is an oncogenic transcription factor and con-
stitutive activation of STAT3 has been observed in numerous
malignancies15,16,21–23. STAT3 is activated by several pro-
inﬂammatory cytokines, including interleukin-6 (IL-6)24–26,
which is a prime target for therapeutic intervention in several
inﬂammatory diseases including rheumatoid arthritis, Still’s dis-
ease and giant cell arthritis. The levels of IL-6 are also increased in
SSc and treatment with monoclonal antibodies against IL-6
receptor may improve clinical outcomes in an inﬂammatory
subgroup of SSc patients27. Of particular interest, STAT3 has also
been linked to mesenchymal tissue responses during development
and in cancer. STAT3 is essentially required for mesoderm
induction in Xenopus embryos28. STAT3 has very recently been
found to promote tumor progression by promoting desmoplastic
reactions and tumor invasion29,30. The identiﬁcation of STAT3 as
a potential therapeutic target in various diseases promoted the
development of STAT3 inhibitors and these efforts generated
numerous candidates22–24,31. First of those inhibitors have
already been tested in clinical trials with promising results.
Several of the upstream kinases that regulate phosphorylation
and thus activation of STAT3, such as JAK2, JNK, and SRC, have
previously been characterized as mediators of non-canonical
TGFβ signaling6,13,17,32. Given the convergence of those media-
tors toward STAT3 activation, we hypothesized that STAT3, in
addition to its central role in inﬂammation, may be a crucial
checkpoint for ﬁbroblast activation and tissue ﬁbrosis.
In this study, we demonstrate that STAT3 signaling is hyper-
active in SSc by the combined action of JAK, SRC, c-ABL, and
JNK kinases. Pharmacological or genetic inactivation of STAT3
inhibits TGFβ-induced ﬁbroblast-to-myoﬁbroblast transition and
collagen release in cultured ﬁbroblasts and ameliorates skin
ﬁbrosis in two mouse models of SSc. We thus demonstrate that
STAT3 is a central integrator of multiple proﬁbrotic signals and a
candidate for molecular-targeted therapies of ﬁbrosis in SSc.
Results
Phosphorylated STAT3 accumulates in ﬁbrotic skin. We ﬁrst
analyze whether STAT3 signaling is activated by analyzing the levels
of STAT3 phosphorylated at tyrosine 705 (P-STAT3), the common
readout for STAT3 activation, in the skin of SSc patients as
compared to age- and sex-matched healthy volunteers. P-STAT3
accumulates in the SSc skin with prominent staining in spindle-
shaped cells in the dermis, whereas only few cells in the dermis
stains positive for P-STAT3 in healthy individuals (Fig. 1a–d).
Costaining of P-STAT3 with vimentin demonstrates that 84± 7%
of SSc ﬁbroblasts stain positive for P-STAT3, as compared to only
34± 3% in healthy skin (P< 0.0001 by Mann–Whitney U-test)
(Fig. 1a, c). Consistent with the persistent activation of SSc ﬁbro-
blasts under culture conditions, we observe an increased accumu-
lation of P-STAT3 in SSc ﬁbroblasts even after several passages in
culture (Fig. 1b, d). The activation of STAT3 signaling in SSc is also
mimicked in experimental models of skin ﬁbrosis. Challenge of
mice with bleomycin or overexpression of TBRact in the skin of
mice signiﬁcantly increases the levels of P-STAT3 as compared to
non-ﬁbrotic control mice (Fig. 1e–j).
TGFβ induces phosphorylation of STAT3. Given the consistent
activation of STAT3 signaling in ﬁbroblasts of SSc patients and in
different experimental models, we speculate that a core pathway
such as TGFβ might drive the activation. Indeed, recombinant
TGFβ induces phosphorylation of STAT3 in cultured ﬁbroblasts,
with maximum accumulation of P-STAT3 observed after 3 h of
TGFβ stimulation (Fig. 2a–d). Immunoﬂuorescence staining further
conﬁrms the activation of STAT3 signaling by TGFβ and demon-
strates nuclear localization of P-STAT3 in TGFβ-stimulated
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Fig. 1 Activation of STAT3 signaling in ﬁbrotic SSc skin. a–d Evaluation of STAT3 signaling in human samples: a Representative images and b quantitative
analysis of immunoﬂuorescence staining for P-STAT3 (left) and total STAT3 (right) co-stained with the vimentin (ﬁbroblast marker) and DAPI (staining
of nuclei) shown at 200-fold and 1000-fold magniﬁcation (n= 12 for SSc and n= 10 for healthy skin). c Western blots and d quantiﬁcation of the levels of
P-STAT3 and total STAT3 in human dermal ﬁbroblasts from 13 SSc patients and 12 healthy individuals. e–g Evaluation of STAT3 signaling in the mouse model of
bleomycin-induced skin ﬁbrosis: e Representative images of immunoﬂuorescence stainings (200-fold and 1000-fold magniﬁcation) showing P-STAT3 (left) and
total STAT3 (right) along with f quantiﬁcation and g conﬁrmation by western blot analyses in the skin of mice injected with NaCl or bleomycin (n≥ 6 for each
group). h–j Evaluation of STAT3 signaling in the mouse model of TBRact-induced ﬁbrosis: h Western blot and i, j immunoﬂuorescence analyses of P-STAT3
expression in the skin of mice injected with TBRact. N≥ 6 for each group with two or three technical replicates for all experiments. Expected band size for
P-STAT3 and STAT3 are 79 kDa (lower faint band) and 86 kDa (higher intense band) and the ladder represents 100 kDa. Beta-actin expected molecular
weight/size is 42 kDa. Horizontal scale bar, 100 μm. Results are shown as median± interquartile range (IQR). Signiﬁcance was determined by Mann–Whitney
test, as compared to healthy volunteers or with non-ﬁbrotic control mice, respectively. *P<0.05; **P<0.01, ***P<0.001
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ﬁbroblasts (Fig. 2b–c). Furthermore, selective inhibition of TGFβ
signaling by SD-208, a TGFβ receptor I inhibitor33, prevents the
upregulation of P-STAT3 in bleomycin-challenged mice (Fig. 2e–f).
Taken together, these results demonstrate that P-STAT3 is over-
expressed in SSc ﬁbroblasts in a TGFβ-dependent manner.
JNK JAK SRC and c-ABL kinases jointly activate
STAT3 signaling in ﬁbroblasts in response to TGFβ. We next
evaluate which upstream kinases mediate phosphorylation of
STAT3 in response to TGFβ. Immunoﬂuorescence staining shows
activation of JAK2, JNK, SRC, and c-ABL signaling in SSc
with increased staining for P-JAK2 (Tyr-1007/1008), P-JNK
(Thr-183/ Tyr-185), P-SRC (Tyr-416), and P-c-ABL (Tyr-412) in
ﬁbroblasts of SSc skin as compared to skin from healthy indivi-
duals (Fig. 3a, b). Stimulation of cultured human dermal ﬁbro-
blasts with recombinant TGFβ also promotes accumulation of
P-JAK2, P-JNK, P-SRC, and P-c-ABL in a time-dependent
manner (Fig. 3c, d). We thus inhibit JAK2, SRC, JNK, and c-ABL,
all of which have also been demonstrated to phosphorylate
STAT3 and are known to transduce the pro-ﬁbrotic effects of
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Fig. 2 TGFβ activates STAT3 signaling in ﬁbroblasts. a Total nuclear and cytoplasmatic levels of P-STAT3 and total STAT3 in human dermal ﬁbroblasts
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evaluated by b immunoﬂuorescence staining and c quantiﬁcation further conﬁrmed by d western blot (n≥ 5 for all). e, f Levels of P-STAT3 in ﬁbroblasts in
bleomycin-challenged mice, treated with SD-208, a selective TGFβ receptor type 1 kinase inhibitor (n≥ 4 with 2 technical replicates for all groups)
analyzed by e western blot and f its quantiﬁcation. Representative blots and images (200-fold magniﬁcation; horizontal scale bar, 100 μm) are shown.
Expected band size for P-STAT3 and STAT3 are 79 kDa (lower faint band) and 86 kDa (higher intense band) and the ladder represents 100 kDa. Beta-actin
expected molecular weight/size is 42 kDa. Results are shown as median± interquartile range (IQR). *P< 0.05, **P< 0.01 vs. healthy dermal ﬁbroblasts or
unstimulated/untreated control ﬁbroblasts, or vehicle-treated, ﬁbrotic mice, respectively
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01236-6
4 NATURE COMMUNICATIONS | 8:  1130 |DOI: 10.1038/s41467-017-01236-6 |www.nature.com/naturecommunications
H
ea
lth
y
10
00
×
P-STAT3 DAPI Vimentin MergeP-JAK2a b
c
d
f
e
H
ea
lth
y
20
0×
SS
c
10
00
×
SS
c
20
0×
H
ea
lth
y
10
00
×
H
ea
lth
y
20
0×
SS
c
10
00
×
SS
c
20
0×
H
ea
lth
y
10
00
×
H
ea
lth
y
20
0×
SS
c
10
00
×
SS
c
20
0×
H
ea
lth
y
10
00
×
H
ea
lth
y
20
0×
SS
c
10
00
×
SS
c
20
0×
La
cZ
10
00
×
La
cZ
20
0×
TB
R
ac
t
10
00
×
TB
R
ac
t
20
0×
La
cZ
10
00
×
La
cZ
20
0×
TB
R
ac
t
10
00
×
TB
R
ac
t
20
0×
La
cZ
10
00
×
La
cZ
20
0×
TB
R
ac
t
10
00
×
TB
R
ac
t
20
0×
La
cZ
10
00
×
La
cZ
20
0×
TB
R
ac
t
10
00
×
TB
R
ac
t
20
0×
N
aC
I
10
00
×
N
aC
I
20
0×
Bl
eo
10
00
×
Bl
eo
20
0×
N
aC
I
10
00
×
N
aC
I
20
0×
Bl
eo
10
00
×
Bl
eo
20
0×
N
aC
I
10
00
×
N
aC
I
20
0×
Bl
eo
10
00
×
Bl
eo
20
0×
N
aC
I
10
00
×
N
aC
I
20
0×
Bl
eo
10
00
×
Bl
eo
20
0×
P-STAT3 DAPI Vimentin MergeP-JNK
P-STAT3 DAPI Vimentin MergeP-JAK2 P-STAT3 DAPI Vimentin MergeP-JNK
P-STAT3 DAPI Vimentin MergeP-JAK2 P-STAT3 DAPI Vimentin MergeP-JNK
P-STAT3 DAPI Vimentin MergeP-c-ABL P-STAT3 DAPI Vimentin MergeP-SRC
P-STAT3 DAPI Vimentin MergeP-c-ABL P-STAT3 DAPI Vimentin MergeP-SRC
P-STAT3 DAPI Vimentin MergeP-c-ABL P-STAT3 DAPI Vimentin MergeP-SRC
0
P-S
TA
T3
P-J
AK
2
P-J
NK
P-c
-AB
L
P-S
RC
P-JAK2 P-JNK P-c-ABL P-SRC
P-J
AK
2
P-S
TA
T3
P-J
NK
P-c
-AB
L
P-S
RC
P-J
AK
2
P-S
TA
T3
P-J
NK
P-c
-AB
L
P-S
RC
2
4
x-
fo
ld
 c
ha
ng
e 
in
po
sit
ive
 fi
br
ob
la
st
 c
ou
nt
x-
fo
ld
 c
ha
ng
e 
in
re
la
tiv
e 
in
te
gr
at
ed
 d
en
sit
y
x-
fo
ld
 c
ha
ng
e 
in
po
sit
ive
 fi
br
ob
la
st
 c
ou
nt
x-
fo
ld
 c
ha
ng
e 
in
po
sit
ive
 fi
br
ob
la
st
 c
ou
nt
6
Healthy SSc
**
**
**
**
**
0
1
2
3
4 0 h 1 h 3 h
6 h 12 h 24 h
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
**
*
*
* *
*
*
*
*
*
*
*
β-actin
c-ABL
P-c-ABL
P-SRC
SRC
P-JNK
JNK
P-JAK2
JAK2
– 1 3 6 12 24
TGFβ stimulation time (h)
40
100
130
100
130
kDa
55
55
70
70
0
1
2
3
4
*
* *
*
*
BleoNaCl
0
1
2
3
4
*
*
*
*
*
TBRactLacZ
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TGFβ from the cell surface to the nucleus13,18,19,34,35. P-JAK2,
P-JNK, P-SRC, and P-c-ABL accumulate in ﬁbroblasts in bleo-
mycin- and TBRact-induced experimental ﬁbrosis to a similar
degree as in human SSc, conﬁrming their suitability to study
STAT3 signaling in SSc (Fig. 3e, f).
In vitro studies demonstrate that not only inhibition of JAK2, but
also of JNK, SRC, and c-ABL by both siRNA-mediated knockdown
and by respective small molecule inhibitors of JAK2, JNK, SRC, and
c-ABL all signiﬁcantly inhibit the TGFβ-induced phosphorylation
of STAT3 (Fig. 4a–f). These results are further substantiated by
demonstrating that individual inactivation of JAK2, JNK, SRC, and
c-ABL all reduced STAT3-dependent reporter activity in TGFβ-
stimulated ﬁbroblasts (Fig. 4g–j). Taken together, these ﬁndings
suggest that JAK2, JNK, SRC, and c-ABL all contribute to the
TGFβ-induced activation of STAT3 in ﬁbroblasts.
To conﬁrm those ﬁndings in vivo, we selectively inhibited
JAK2, JNK, SRC, and c-ABL by selective small molecule
inhibitors in the experimental murine models of bleomycin-
induced skin ﬁbrosis and TBRact-induced skin ﬁbrosis. Indivi-
dual inhibition of JAK2, JNK, SRC, or c-ABL signaling all
signiﬁcantly ameliorates the bleomycin-induced accumulation of
P-STAT3 (Fig. 5a–c). Consistently, treatment with small molecule
inhibitors of either JAK2, JNK, SRC, or c-ABL all reduces the
accumulation of phosphorylated STAT3 in mice overexpressing
TBRact (Supplementary Fig. 2). However, despite relatively high
doses of each inhibitor, none of the treatments completely
abrogates the activation of STAT3 signaling by bleomycin. These
data demonstrate that the activation of STAT3 in activated
ﬁbroblasts results from the combined activation of JAK2, JNK,
SRC, and c-ABL kinases.
As recent ﬁndings suggest that JAK1 might also be capable of
activating STAT3, either directly32,36 or indirectly by transpho-
sphorylation of JAK237, we decide to further investigate the
effects of JAK1 inhibition on TGFβ-induced activation of STAT3.
Inhibition of JAK1 by siRNA-mediated knockdown or small
molecule inhibitors targeting JAK1 and JAK2 partially reduces
100
100
55
kDa
0.00
0.05
0.10
0.15
0.20
0.25
TGFβ
P-STAT3
STAT3
β-actin
co
TGFβ
JAK2 inh
JAK2 inh/TGFβ
JNK inh
JNK inh/TGFβ
c-ABL inh
c-ABL inh/TGFβ
SRC inh
SRC inh/TGFβ
ba
c d e f
g h i j
0
20
40
60
80
100
0
5
10
15
20
0
2
4
6
8
0
50
100
150
200
JAK2 
siRNA
JAK2
Control 
siRNA
R
el
at
ic
e 
Lu
c 
ac
tiv
ity
R
el
at
ic
e 
Lu
c 
ac
tiv
ity
R
el
at
ic
e 
Lu
c 
ac
tiv
ity
R
el
at
ic
e 
Lu
c 
ac
tiv
ity
0.0
0.1
0.2
0.3
0.4
100
40
100
100
100
40
130
100
c-ABL 
siRNA
c-ABL
Control 
siRNA
0.0
0.5
1.0
1.5
kDakDakDa
70
100
SRC 
siRNA
P-STAT3
STAT3
β-actin
P-STAT3
STAT3
β-actin
P-STAT3
STAT3
β-actin
P-STAT3
STAT3
β-actin
SRC
TGFβ – + – +TGFβ – + – +TGFβ – + – +TGFβ – + – +
Control 
siRNA
0.0
0.2
0.4
0.6
0.8
100
40
kDa
JNK 
siRNA
JNK
Control 
siRNA
0.0
0.1
0.2
0.3
0.4
100
40
55
100
Control
– + – + – + – + – +
JAK2
inhibitor
JNK
inhibitor
x-
fo
ld
 c
ha
ng
e 
in
 P
-S
TA
T3
/
β-a
ct
in
 in
te
gr
at
ed
 d
en
sit
y
x-
fo
ld
 c
ha
ng
e 
in
 P
-S
TA
T3
/
β-a
ct
in
 in
te
gr
at
ed
 d
en
sit
y
x-
fo
ld
 c
ha
ng
e 
in
 P
-S
TA
T3
/
β-a
ct
in
 in
te
gr
at
ed
 d
en
sit
y
x-
fo
ld
 c
ha
ng
e 
in
 P
-S
TA
T3
/
β-a
ct
in
 in
te
gr
at
ed
 d
en
sit
y
x-
fo
ld
 c
ha
ng
e 
in
 P
-S
TA
T3
/
β-a
ct
in
 in
te
gr
at
ed
 d
en
sit
y
* *
*
*
*
* *
* * * *
* *
* *
* *
** *
* *
c-ABL
inhibitor
SRC
inhibitor
Fig. 4 Proﬁbrotic kinases pathways converge on P-STAT3 in vitro. a, b Effects of pharmacologic inhibition of JAK2, JNK, c-ABL, and SRC kinases on the
levels of P-STAT3 in TGFβ-stimulated ﬁbroblasts in vitro as analyzed by a western blot and b its quantiﬁcation (n≥ 4 with 2 technical replicates per
condition for all experiments). Representative images and quantiﬁcation of four independent experiments are shown. c–f Effects of siRNA-mediated
knockdown of c JAK2, d JNK, e c-ABL, and f SRC, respectively, on levels of P-STAT3 in healthy human dermal ﬁbroblasts stimulated with TGFβ, as shown
by representative western blots and quantiﬁcations (n≥ 4 with 2 technical replicates per group for all experiments). JAK2 (expected molecular size,
132 kDa), JNK (expected molecular size, 49 and 55 kDa), c-ABL (expected molecular size, 125–135 kDa), and SRC (expected molecular size, 60 kDa) are
represented by ladders showing 100, 55, 130, and 70 kDa, respectively. Beta-actin expected molecular weight/size is 42 kDa. g–j Relative luciferase activity
in ﬁbroblasts transfected with STAT3 luciferase reporter plasmid and treated with g the JAK2 inhibitor TG101209, h the JNK inhibitor SP600125, i the
c-ABL inhibitor imatinib mesylate and j the SRC inhibitor SU6656, independently with or without TGFβ stimulation (n= 3 independent experiments with 2
technical replicates per group for all experiments). Luciferase activity was normalized against a non-inducible luciferase construct. Results are shown as
median± interquartile range (IQR). Signiﬁcance was determined by Mann–Whitney test, as compared to untreated unstimulated ﬁbroblasts or untreated
TGFβ-stimulated ﬁbroblasts, respectively. *P< 0.05; **P< 0.01, ***P< 0.001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01236-6
6 NATURE COMMUNICATIONS | 8:  1130 |DOI: 10.1038/s41467-017-01236-6 |www.nature.com/naturecommunications
STAT3 activation in human dermal ﬁbroblasts (Supplementary
Fig. 1).
We are further interested to study potential crosstalk between
STAT3 and SMAD signaling in TGFβ-stimulated ﬁbroblasts.
We ﬁrst analyze the kinetics of the activation of both pathways
by analyzing the accumulation of P-STAT3 and P-SMAD3
upon stimulation with TGFβ. The accumulation of P-SMAD3
precedes the accumulation of P-STAT3 with initial increases
after 15min for P-SMAD3 and 2–3 h for P-STAT3 (Supplementary
Fig. 3a). Co-immunoprecipitation (CoIP) studies with SMAD3
antibodies demonstrate that SMAD3 binds to non-phosphorylated
STAT3 in dermal ﬁbroblasts (Supplementary Fig. 3b). The
interaction between SMAD3 and non-phosphorylated STAT3 is
further enhanced by coincubation of ﬁbroblasts with the STAT3
dimerization inhibitor S3I-201, a small molecule inhibitor that
interferes with the dimerization of STAT331, likely by increasing the
availability of monomeric STAT3 in the cytoplasm as a binding
partner for SMAD3. Incubation with S3I-201, however, does not
promote binding of SMAD3 to P-STAT3. Consistent with a
recently proposed model that the binding of non-phosphorylated
SMAD3 to STAT3 may inhibit STAT3 signaling36, siRNA-
mediated knockdown of SMAD3 promotes STAT3 signaling with
a trend toward increased levels of P-STAT3 and signiﬁcantly
increases STAT3-dependent transcription in reporter assays
(Supplementary Fig. 3c–f). However, inhibition of STAT3 dimer-
ization using S3I-201 has no signiﬁcant impact on TGFβ-induced
SMAD3 phosphorylation in cultured ﬁbroblasts and on SMAD3-
dependent transcription in reporter studies, suggesting a predomi-
nantly unidirectional regulation.
Inactivation of STAT3 inhibits TGFβ-induced myoﬁbroblast
differentiation and collagen release. We wonder whether
the TGFβ-induced activation of STAT3 may contribute to
the stimulatory effects of TGFβ on ﬁbroblasts. To target
STAT3 signaling, we ﬁrst use S3I-201, a small molecule inhibitor
that binds to the STAT3–SH2 domain to block STAT3
phosphorylation and STAT3 DNA binding24,38. Treatment with
S3I-201 inhibits the transcription of the TGFβ target gene Ctgf and
reduces the differentiation of resting ﬁbroblasts into myoﬁbro-
blasts with impaired upregulation of αSMA mRNA and
protein and decreased formation of stress ﬁbers upon stimulation
with TGFβ (Fig. 6a–f). Moreover, inhibition of STAT3 also
reduces the stimulatory effects of TGFβ on collagen synthesis with
decreased mRNA levels of col1a1 and col1a2 and reduced release
of collagen protein (Fig. 6c–e). To exclude that the anti-ﬁbrotic
a
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effects of S3I-201 are due to off-target effects, we conﬁrm these
results by a genetic approach using ﬁbroblasts depleted of STAT3.
Consistent with the ﬁndings obtained with S3I-201, ﬁbroblasts
deﬁcient in STAT3 are less sensitive to the stimulatory effects of
TGFβ with decreased expression of Ctgf, impaired myoﬁbroblast
differentiation and reduced collagen synthesis (Fig. 6g–l).
Fibroblast-speciﬁc knockout of STAT3 ameliorates experi-
mental ﬁbrosis. We next investigate whether inactivation of STAT3
exerts anti-ﬁbrotic effects in murine models of SSc. As
STAT3 signaling is particularly active in ﬁbroblasts and as mice with
complete, non-conditional knockout of STAT3 are not viable39,40, we
generate mice with selective and inducible deletion of STAT3 in
ﬁbroblasts. Knockdown of STAT3 in ﬁbroblasts does not alter the
basal skin histology, leukocyte inﬁltration, or the collagen content in
the absence of pro-ﬁbrotic stimuli (Figs 7 and 8 and Supplementary
Fig. 4). Furthermore, the ﬁbroblast-speciﬁc knockdown of STAT3 in
bleomycin-challenged mice does not have any noticeable or adverse
effect on STAT3 activation in other cell populations in the murine
skin (Supplementary Figs. 5–9).
However, mice with conditional deletion of STAT3
in ﬁbroblasts are protected from experimental ﬁbrosis.
Consistent with the inhibitory effects of STAT3 inactivation on
TGFβ-induced ﬁbroblast activation in vitro, mice lacking
STAT3 selectively in ﬁbroblasts are less sensitive to TBRIact-
induced ﬁbrosis and demonstrate reduced dermal thickening,
decreased myoﬁbroblast counts, and lower hydroxyproline levels
compared to TBRIact mice with normal STAT3 expression
(Fig. 7a–g). Consistent with decreased myoﬁbroblast counts and
the reduced collagen deposition, the mRNA levels of Acta2,
Col1a1, and Col1a2 are also reduced in mice with ﬁbroblast-
speciﬁc deletion of STAT3-overexpressing TBRIact as compared
to control littermates (Fig. 7c–e).
The mRNA levels of the TGFβ-regulated genes Thbs1 and
Comp have recently been shown to correlate with the changes in
Control + sham TGFβ + sham Control + S3l-201 TGFβ + S3l-201
0
1
2
3
0
5
10
15
20
25
*
*
* *
* *
*
**
*
**
**
**
**
*
*
*
*****
**
*
x-
fo
ld
 c
ha
ng
e 
in
 C
TG
F 
m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
 A
CT
A2
 m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
 C
ol
1a
1 
m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
 C
ol
1a
2 
m
R
N
A
0
2
4
6
0
1
2
3
0
1
2
3
x-
fo
ld
 c
ha
ng
e 
in
 c
ol
la
ge
n 
pr
ot
ei
n
a b c d e
Control + LacZ TGFβ + LacZ TGFβ + CreControl + Cre
0
2
4
6
8
x-
fo
ld
 c
ha
ng
e 
in
 A
CT
A2
 m
R
N
A 
0
2
4
6
8
x-
fo
ld
 c
ha
ng
e 
in
 C
TG
F 
m
R
N
A 
0
2
4
6
x-
fo
ld
 c
ha
ng
e 
in
 C
ol
1a
1 
m
R
N
A 
0
1
2
3
x-
fo
ld
 c
ha
ng
e 
in
 C
ol
1a
2 
m
R
N
A
0
2
4
6
8
10
12
x-
fo
ld
 c
ha
ng
e 
in
 c
ol
la
ge
n 
pr
ot
ei
nh i
j k l
f
St
re
ss
 fi
be
rs
Control + S3I-201
Control + sham Control + LacZ
Control + Cre
Human fibroblasts g STAT3+/+ murine fibroblasts
St
re
ss
 fi
be
rs
TGFβ + S3I-201
TGFβ + sham TGFβ + LacZ
TGFβ + Cre
Fig. 6 Inactivation of STAT3 inhibits TGFβ-induced myoﬁbroblast differentiation and collagen release. a–f Effect of the STAT3 inhibitor S3I-201 on
the mRNA levels of a CTGF, b ACTA2, c COL1A1, d COL1A2, and e collagen protein (n= 4–7 and 2 technical replicates for all experiments) in human
dermal ﬁbroblasts. f Representative images of immunoﬂuorescence staining for stress ﬁbers at 200-fold magniﬁcation. Horizontal scale bar, 100 μm.
g–l Responsiveness of AAV-Cre virus-infected mouse ﬁbroblasts from STAT3ﬂ/ﬂ mice to TGFβ stimulation, as compared to AAV-LacZ virus-infected
ﬁbroblasts, which served as control: g Representative images of immunoﬂuorescence staining for stress ﬁbers at 200-fold magniﬁcation. Horizontal scale
bar, 100 μm. mRNA levels of h Ctgf, i Acta2, j Col1a1, k Col1a2, and l collagen protein (n= 6 with 2 technical replicates for all experiments). Results are
shown as median± interquartile range (IQR). Signiﬁcance was determined by Mann–Whitney test, as compared to the unstimulated control ﬁbroblasts or
TGFβ-stimulated control ﬁbroblasts, respectively. *P< 0.05; **P< 0.01, ***P< 0.001. AAV adeno-associated virus
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01236-6
8 NATURE COMMUNICATIONS | 8:  1130 |DOI: 10.1038/s41467-017-01236-6 |www.nature.com/naturecommunications
Tam+TBRactCO+LacZ CO+TBRact Tam+LacZa
X-
fo
ld
 c
ha
ng
e 
in
de
rm
al
 th
ick
ne
ss
b
0
1
2
3 * *
LacZ
TBRact
Tam+LacZ
Tam+TBRact
x-
fo
ld
 c
ha
ng
e 
in
Ac
ta
2 
m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
Co
l1
a1
 m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
Ct
gf
 m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
Pa
i-1
 m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
Co
l1
a2
 m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
co
lla
ge
n 
pr
ot
ei
n
x-
fo
ld
 c
ha
ng
e 
in
m
yo
fib
ro
bl
as
t c
ou
nt
x-
fo
ld
 c
ha
ng
e 
in
Th
bs
1 
m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
Co
m
p 
m
R
N
A
x-
fo
ld
 c
ha
ng
e 
in
P-
ST
AT
3/
ST
AT
3
c d e f g
h i kj l
0
1
2
3
4 ** **
0.0
0.5
1.0
1.5
2.0
2.5 ** *
0
1
2
3
4
5
***
0
2
4
6
8 *** *
0
1
2
3 **
0.0
0.5
1.0
1.5
2.0 ** **
0
1
2
3
4
5 ** **
0
2
4
6
8
***
0
1
2
3
4
5 ** *
0
2
4
6 ** *
P-STAT3 DAPI Vimentin Merge STAT3 DAPI MergeVimentin
P-STAT3 DAPI Vimentin Merge STAT3 DAPI MergeVimentin
m
n
Ta
m
+L
ac
Z
20
0×
La
cZ
20
0×
Ta
m
+T
BR
ac
t
20
0×
TB
R
ac
t
20
0×
Ta
m
+L
ac
Z
10
00
×
La
cZ
10
00
×
Ta
m
+T
BR
ac
t
10
00
×
TB
R
ac
t
10
00
×
Ta
m
+L
ac
Z
20
0×
La
cZ
20
0×
Ta
m
+T
BR
ac
t
20
0×
TB
R
ac
t
20
0×
Ta
m
+L
ac
Z
10
00
×
La
cZ
10
00
×
Ta
m
+T
BR
ac
t
10
00
×
TB
R
ac
t
10
00
×
Fig. 7 Fibroblast-speciﬁc knockout of STAT3 reduced the effects of TBRact-induced skin ﬁbrosis. a Representative histological sections stained with
hematoxylin and eosin (top) and trichrome (bottom). b Dermal thickness, c–e mRNA levels of Acta2, Col1a1, and Col1a2, respectively, f hydroxyproline
content, g myoﬁbroblast count, and h–k levels of h Ctgf mRNA, i Pai-1 mRNA and of the proposed biomarkers, j Thbs1 mRNA and k Comp mRNA.
m, n Representative immmunoﬂuorescence stainings of P-STAT3 (left) and total STAT3 (right) at 200-fold and 1000-fold magniﬁcation, respectively,
along with their l quantitative analyses. All experiments were performed in dermal tissue sections from the experimental mouse model of TBRact-induced
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the modiﬁed Rodnan skin score41–44 as the common
clinical readout of skin ﬁbrosis and changes in the mRNA levels
of Thbs1 and Comp in ﬁbrotic skin are thus considered
as potential biomarkers for SSc. The mRNA levels of Thbs1
and Comp decrease in mice with ﬁbroblast-speciﬁc deletion of
STAT3 (Fig. 7j, k). The mRNA levels of other TGFβ-regulated
genes, such as Pai-1 and Ctgf, are also found to be reduced
(Fig. 7h, i).
In addition to TBRIact-induced ﬁbrosis, mice with ﬁbroblast-
speciﬁc knockout of STAT3 are also protected from bleomycin-
induced skin ﬁbrosis with reduced dermal thickening, myoﬁbro-
blast differentiation, and hydroxyproline content in lesional skin
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compared to control mice (Fig. 8a–g). The levels of Acta2, Col1a1,
Col1a2, Thbs1, Comp, Pai-1, and Ctgf mRNA lessen in mice with
ﬁbroblast-speciﬁc deletion of STAT3 upon challenge with
bleomycin than in control littermates (Fig. 8h–n).
Pharmacological inhibition of STAT3 exerts potent anti-
ﬁbrotic effects in experimental models of SSc. To test the
translational potential of those ﬁndings, we next use S3I-201 to
inactive STAT3 in experimental ﬁbrosis. Treatment with S3I-201
exerts potent anti-ﬁbrotic effects in TBRIact- and bleomycin-induced
skin ﬁbrosis at well-tolerated doses (Figs. 9 and 10). S3I-201 effec-
tively reduces TBRIact-induced dermal thickening, myoﬁbroblast
differentiation, and collagen accumulation (Fig. 9a–h).
Treatment with S3I-201 also strongly ameliorates bleomycin-
induced skin ﬁbrosis (Fig. 10a–h). In both models, treatment with
S3I-201 reduces the mRNA levels of Acta2, Col1a1, Col1a2,
Thbs1, Comp, Pai-1, and Ctgf (Figs. 9 and 10i–l).
Of note, no evidence of toxicity of anti-ﬁbrotic doses of S3I-201
has been observed, either clinically or on necroscopy.
Discussion
In this study, we characterize STAT3 as an intracellular mediator
of the pro-ﬁbrotic effects of TGFβ. We show that knockdown of
STAT3 in cultured ﬁbroblasts by siRNA or by pharmacological
inactivation prevents TGFβ-induced differentiation of resting
ﬁbroblast into myoﬁbroblasts and signiﬁcantly reduces the
stimulatory effect of TGFβ on collagen release. Moreover,
ﬁbroblast-speciﬁc knockout of STAT3 strongly ameliorates
TBRact-induced ﬁbrosis, further highlighting the crucial role of
STAT3 in TGFβ-induced ﬁbroblast activation. We establish that
pharmacological or genetic inhibition of STAT3 also reduces the
levels of TGFβ-target genes in skin experimental ﬁbrosis,
including those of potential biomarkers such as Thbs1 and Comp.
TGFβ also activates STAT3 signaling and promotes accumulation
of P-STAT3. The stimulatory effects of TGFβ on STAT3 are not
restricted to ﬁbroblasts and the skin, but have also been observed
in other cell types and tissues such as follicular T-helper cells and
hepatic stellate cells32,45–47. Together, these data demonstrate that
STAT3 acts as a non-canonical downstream mediator to transmit
the proﬁbrotic effects of TGFβ.
Although JAK2 is a key regulator of STAT3 phosphorylation,
several other kinases have also been shown to phosphorylate and
activate STAT3 in a JAK2-independent manner16,19,48,49. As
inhibition of JAKs would not block those alternative pathways
of STAT3 phosphorylation, targeting of JAK2 may thus not
completely abrogate the pathological activation of STAT3 in
ﬁbrotic diseases. Indeed, we elucidate that STAT3 is phosphory-
lated not only by JAK2, but that SRC, c-ABL, and JNK kinases
also contribute signiﬁcantly to the phosphorylation of STAT3 in
cultured ﬁbroblasts and in ﬁbrotic tissues. In addition, JAK1 also
seems to contribute to activation of STAT3 in ﬁbroblasts in
response to TGFβ, but further studies are required to determine
whether JAK1 directly phosphorylates STAT3 in this context or
whether the effects or mediated indirectly via JAK1-dependent
activation of JAK232,36,37. These ﬁndings demonstrate that the
signals transmitted through JAK2, SRC, c-ABL, and JNK all
converge on STAT3. This is particularly intriguing as all these
kinases are hyper-activated in SSc and have been shown to
contribute to the aberrant activation of ﬁbroblasts13,34,35,50. In
addition to these kinases, serine/threonine kinases, such as CK2,
have also been implicated in the pathogenesis of SSc36. Whether
CK2 and other serine/threonine kinases are also capable of
activating STAT3 signaling remains to be determined. These data
provide evidence that STAT3 serves as a key molecular check-
point for ﬁbroblast activation by integrating and converting
activation of JAK2, SRC, c-ABL, and JNK kinases into
pro-ﬁbrotic responses with induction of myoﬁbroblast differ-
entiation and upregulation of collagen release.
We also investigate the crosstalk of STAT3 signaling with
canonical TGFβ/SMAD signaling. In some contexts, STAT3 and
SMAD3 signaling pathways have been reported complementary to
each other32,36, whereas recent data generated in HaCaT cells
suggest that STAT3 signaling may also attenuate TGFβ-induced
SMAD signaling51. We demonstrate that the activation of
SMAD3 signaling precedes the activation STAT3 signaling in
primary human dermal ﬁbroblasts. Moreover, in this setting,
SMAD3 binds to non-phosphorylated STAT3, but not to P-STAT3.
Knockdown of SMAD3 enhances TGFβ-induced STAT3 signaling,
whereas inhibition of STAT3 does not promote SMAD signaling.
These ﬁndings provide evidence that the binding of non-
phosphorylated SMAD3 to STAT3 may inhibit STAT3 signaling
in ﬁbroblasts in the context of ﬁbrosis, a model that is consistent
with recent ﬁndings in hepatic stellate cells32,36. Activation of
SMAD signaling in ﬁbrotic diseases may thus further boost TGFβ-
dependent activation of STAT3 in addition to direct phosphoryla-
tion by the upstream kinases SRC, JAK2, c-ABL, and JNK.
The central role of STAT3 as an integrator of pro-ﬁbrotic
signals from several upstream kinases suggests STAT3 as a
potential target for anti-ﬁbrotic therapies. Indeed, we demon-
strate using genetic approaches as well as a selective pharmaco-
logical inhibition of STAT3 that inactivation of STAT3 signaling
exerts potent anti-ﬁbrotic effects. Inactivation of STAT3 inhibits
bleomycin-induced ﬁbrosis as a model of early, inﬂammation-
driven ﬁbrosis, but also demonstrate potent anti-ﬁbrotic effects in
TBRact-induced ﬁbrosis as a model of late, non-inﬂammatory
stages of SSc with endogenous activation of ﬁbroblasts52.
Targeting STAT3 may thus be effective in different stages and
different subpopulation of SSc patients. Moreover, treatment with
S3I-201 is not only effective in preventive settings, but also in
therapeutic regimens. When treatment with S3I-201 is initiated
after ﬁbrosis has already been established, inhibition of STAT3
does not only prevent further progression of ﬁbrosis despite
ongoing challenge with bleomycin, but induces regression of
ﬁbrosis to below-pre-treatment levels.
Although our in vitro studies on cultured ﬁbroblasts and our
in vivo data on mice with ablation of STAT3 speciﬁcally in
ﬁbroblasts demonstrate that ﬁbroblasts are key-target cells, the
anti-inﬂammatory effects of STAT3 inhibitors likely contribute to
the anti-ﬁbrotic effects of pharmaceutical STAT3 inhibition.
STAT3 transmits the intracellular signals of multiple cytokines,
such as IL-1β, IL-6, or TNFα, that are known to promote
Fig. 9 Pharmacological inhibition of STAT3 induces the regression of TBRact-induced experimental skin ﬁbrosis. a–o Treatment of TBRact-induced skin
ﬁbrosis with the STAT3 inhibitor S3I-201 in mice (DBA/2 background, 12 weeks of age). a Representative histological sections stained with hematoxylin
and eosin (top) and trichrome (bottom). b Dermal thickness, c western blot analysis of P-STAT3, shown by the ladder representing 100 kDa (expected
intense upper band size, 86 kDa and lower faint band size, 79 kDa). Beta-actin (expected molecular weight/size, 42 kDa) is shown by ladder at 40 kDa.
d–f mRNA levels of d Acta2, e Col1a1, and f Col1a2, g hydroxyproline content, h myoﬁbroblast counts and levels of i Ctgf mRNA, j Pai-1 mRNA and of the
proposed biomarkers, k Thbs1 mRNA, and l Comp mRNA. m–o Immunoﬂuorescence analysis including n, o representative immunoﬂuorescence stainings of
P-STAT3 (left) and total STAT3 (right) at 200-fold and 1000-fold magniﬁcation, respectively, along with their m quantitative analyses. N≥ 6 mice with 2
technical replicates per group for all experiments. Results are shown as median± interquartile range (IQR). Horizontal scale bar, 100 μm. Signiﬁcance was
determined by Mann–Whitney test, as compared to vehicle-treated, ﬁbrotic mice, respectively. *P< 0.05; **P< 0.01***; P< 0.001
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inﬂammation in ﬁbrotic diseases including SSc26,27,53–55. Inhibi-
tion of IL-6 signaling may be of particular interest for the
pathogenesis of SSc, as treatment with anti-IL6-receptor anti-
bodies may improve the clinical outcome in an inﬂammatory
subgroup of SSc patients27,56. Although approximately only
one-third of SSc patients shows an inﬂammatory gene expression
proﬁle in ﬁbrotic skin or presents with clinical features of
inﬂammation57–60, inhibition of inﬂammation may contribute to
the efﬁcacy of STAT3 inhibitors in particular in the inﬂammatory
subset of patients. For the same reasons, inhibition of STAT3 may
not only be effective in classical ﬁbrotic diseases, but may also
ameliorate pathologic repair responses in inﬂammatory diseases.
For example, treatment with Stattic, a ﬁrst-generation inhibitor of
STAT3, also improves strictures in Crohn’s diseases61; treatment
b
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with a small STAT3 inhibitor STA-21, ameliorates psoriasis-like
skin lesions not only in experimental mouse models, but may also
improve human psoriasis21,53,62. The prominent role of STAT3 in
the pathogenesis of psoriasis is intriguing, i.p. as we also observe
staining for P-STAT3 in keratinocytes in our mouse models.
However, the levels of nuclear P-STAT3 in epidermal keratino-
cytes are not altered by induction of ﬁbrosis with bleomycin
(Supplementary Fig. 10 and Supplementary Movies 1 and 2).
These ﬁndings may have direct translational implications.
Several approaches to target STAT3 are currently in clinical
development with small molecular inhibitors of STAT3 dimer-
ization and oligodeoxynucleotides being most common. Indeed,
more than 10 different clinical trials investigating STAT3 inhi-
bitors in various solid tumors, hematologic neoplasms, or psor-
iasis are currently ongoing or have already been completed (www.
clinicaltrials.gov), highlighting that STAT3 is considered as a
prime target for pharmaceutical intervention.
Methods
Patients. Dermal ﬁbroblasts were isolated from skin biopsies of 27 SSc patients
fulﬁlling the criteria for SSc63 (Supplementary Table 1) and from skin biopsy
samples of 31 healthy individuals matched for age and sex as described. Clinical
characteristics are provided in Supplementary Table 1. The human studies were
approved by the Ethical Committee of the Medical Faculty of the University of
Erlangen-Nuremberg. All patients and controls signed a consent form approved by
the local institutional review board.
All patients had SSc according to the 2013 ACR/EULAR64. The disease subset
was determined according to the criteria proposed by LeRoy et al. Disease duration
was measured from the onset of the ﬁrst non-Raynaud symptoms attributable to
SSc. Pulmonary arterial hypertension was diagnosed by right heart catheterization.
Disease activity was determined using the EULAR Systemic Sclerosis Activity
Score. Patients with scores of ≥3 were classiﬁed as having active disease. DMARD,
disease-modifying antirheumatic drug; F, female; M, male; NSAID, non-steroidal
anti-inﬂammatory drug.
Cell culture. Murine and human dermal ﬁbroblasts were obtained from sterile
3 mm × 3mm skin punches from murine or patients. The skin fragments were
further fragmented using sterile scalpel and digested with Dispase II solution (from
Bacillus polymyxa, Gibco BRL, Darmstadt, Germany) (0.8 mg/ml in PBS) for 3 h at
37 °C and 800 rpm. The digested sample was ﬁltered using 100 µm nylon ﬁlter and
centrifuged at 1400 rpm for 5 min. The pellet was resuspended in Dulbecco’s
modiﬁed Eagle’s medium-Ham’s F-12 (DMEM) containing 10% fetal bovine serum
and put in culture ﬂasks. Before an experiment, dermal ﬁbroblasts were serum-
starved in DMEM containing 0.1% fetal bovine serum for 24–48 h. In selective
experiments, serum-starved cells were incubated with recombinant human TGFβ-1
(10 ng/ml) (R&D Systems, Abingdon, UK), the STAT3 inhibitor S3I-201 (15 µM)
(Selleckchem, Houston, USA), the JAK2 inhibitor TG101209 (500 nM) (Sell-
eckchem), the JAK1/2 inhibitor Ruxolitinib (5 µM) (LC Laboratories, Massachu-
setts, USA), the SRC inhibitor SU6656 (500 nM) (Calbiochem, Seattle, USA), the
JNK inhibitor SP600125 (500 nM) (Tocris Bioscience, Bristol, UK), and the c-ABL
inhibitor imatinib mesylate (500 nM) (Novartis, Basel, Switzerland). To delete
STAT3 from cultured murine ﬁbroblasts isolated from STAT3ﬂ/ﬂ Cre−/− mice,
ﬁbroblasts were infected with type 5 adeno-associated viruses (AAV) encoding for
Cre recombinase at an IFU of 80/cells. AAV encoding for LacZ served as controls.
Transfections and luciferase reporter assays. Human dermal ﬁbroblasts were
transfected with reporter plasmid constructs or siRNAs using using the Nucleo-
fection technique and Nucleofector Solution V (Lonza, Cologne, Germany) using
the manufacturer’s recommended protocol. Experiments were conducted 24–48 h
after transfection and thereafter cells were harvested. Gene silencing was achieved
by nucleofecting 3 μg pre-designed siRNA duplexes against JAK2, JAK1, SRC, c-
ABL, and SMAD3 (all Eurogentec, Seraing, Belgium) and 100 nM SignalSilence
siRNA I for SAPK/JNK (Cell Signaling Technology, #6232). The transfection
efﬁciency was determined by western blot analysis. Non-targeting siRNAs (nt
siRNA) (Life Technologies, Darmstadt, Germany) served as controls. The sequences
of the pre-designed sense siRNAs are described in Supplementary Table 2.
Cignal Lenti STAT3 Reporter (luc) Kit and Cignal SMAD Reporter (luc) Kit
from Qiagen (Hilden, Germany) were used to determine STAT3- and SMAD3-
dependent reporter activities. Dual-luciferase activities were determined by using
Luminoskan™ Ascent Microplate-Luminometer (ThermoFisher Scientiﬁc, Madrid,
Spain). The constitutively expressed non-inducible Renilla luciferase activity served
as internal control for normalizing transfection efﬁciencies.
Quantitative real-time PCR. Gene expression was quantiﬁed by SYBR Green real-
time PCR using the ABI Prism 7300 Sequence Detection System (Life Technolo-
gies). Samples without enzyme in the reverse transcription reaction (non-RT
controls) were used as negative controls. Unspeciﬁc signals caused by primer
dimers were excluded by non-template controls and by dissociation curve analysis.
Beta-actin (ACTB) was used to normalize for the amounts of cDNA within each
sample. All primer sequences are presented in Suppplementary Table 3.
Western blot analysis. Proteins were separated by SDS-PAGE and transferred to
polyvinylidene diﬂuoride membrane, which was incubated overnight with the
appropriate primary antibody. The primary antibodies included mouse anti-STAT3
(1:1000), rabbit anti-P-STAT3 (Tyr705, dilution 1:500), rabbit anti-JAK2 (dilution
1:1000), rabbit anti-P-SRC (Tyr 416, dilution 1:500), rabbit anti-SRC (dilution
1:800), rabbit anti-c-ABL (dilution 1:800), rabbit anti P-c-ABL (Tyr 245/412,
dilution 1:500), rabbit and anti-JNK (SAPK/JNK, dilution 1:500) from Cell Sig-
naling Technology (Frankfurt, Germany); rabbit anti-JAK1 (1:200), goat anti-P-
JAK1 (Tyr 1022, dilution 1:200), and rabbit anti-P-JAK2 (Tyr 1007/1008, dilution
1:200) from Santa Cruz Biotechnology (Heidelberg, Germany); rabbit anti-SMAD3
(dilution 1:500), rabbit anti-P-SMAD3 (dilution 1:250), and rabbit anti-P-JNK
(Thr183/Tyr185, dilution 1:500) from Abcam (Cambridge, UK) and rabbit anti-P-
SRC (dilution 1:500) from MyBioSource (San Diego, USA). Horseradish peroxidase-
conjugated antibodies (Dako, Hamburg, Germany) were used as secondary anti-
bodies. Blots were visualized using enhanced chemiluminescence (ECL from GE
Healthcare, Braunschweig, Germany). Beta-actin (Sigma-Aldrich, Deisenhofen,
Germany) or Lamin A/C (Cell Signaling Technology) antibodies served as controls
for equal loading. PageRuler™ Prestained Protein Ladders #26616 and #26619 from
ThermoFisher Scientiﬁc (Darmstadt, Germany) were used. Bands were quantiﬁed
using the ImageJ Software (NIH, version 1.49). The original uncropped scans of
western blots presented in the main ﬁgures are shown in Supplementary Fig. 11.
CoIP. Fibroblasts were collected in lysis buffer composed of 400 mM NaCl, 20 mM
HEPES (pH 7.9), and 1 mM EDTA. An aliquot of 20 μg from the lysates was used
as input. Cell extracts were incubated with 20 μl Protein A/G Sepharose and 3 μg of
SMAD3 or normal IgG antibodies (no. sc-5569, no. sc-101154, and no. sc-2027, all
Santa Cruz Biotechnology, Heidelberg, Germany). Unbound proteins were
removed by washing with 0.05% NP-40. Sepharose-bound protein complexes were
analysed by western blotting.
Quantiﬁcation of collagen protein. Total soluble collagen in cell culture super-
natants was quantiﬁed using the SirCol collagen assay (Biocolor, Belfast, Northern
Ireland) as described previously50,65. Brieﬂy, cell culture supernatant was mixed
with sirius red dye for 30 min at room temperature. After centrifugation, the pellet
was dissolved in alkali reagent. Measurement was performed using a SpectraMax
190 microplate spectrophotometer (Molecular Devices, Biberach an der Riß,
Germany) at a wavelength of 540 nm.
Immunohistochemistry and immunoﬂuorescence staining. Formalin-ﬁxed,
parafﬁn-embedded skin sections or 4% PFA-ﬁxed, 0.25% Triton X-100-
permeabilized cells were stained with appropriate primary antibodies, including
mouse anti-STAT3 (dilution 1:200) (Cell Signaling Technology) and rabbit anti-P-
STAT3 (dilution 1:500) (Abcam). For double-staining experiments, the samples
were incubated again with primary antibodies against P-SRC (dilution 1:500),
P-JAK2 (dilution 1:500), P-c-ABL (dilution 1:300), and P-JNK (dilution 1:500).
Fibroblasts were stained speciﬁcally with vimentin (Sigma-Aldrich) overnight at
4 °C. HRP-conjugated or Alexa Fluor antibodies (Life Technologies, Darmstadt,
Germany) were used as secondary antibodies. Fibroblasts incubated with isotype
Fig. 10 Pharmacological inhibition of STAT3 exerts potent anti-ﬁbrotic effects in bleomycin-induced experimental skin ﬁbrosis model. a–o Treatment of
bleomycin-induced skin ﬁbrosis with the STAT3 inhibitor S3I-201 in mice (DBA/2 background, 12 weeks of age). a Representative histological sections stained
with hematoxylin and eosin (top) and trichrome (bottom). b Dermal thickness, c western blot analysis of P-STAT3, shown by the ladder representing 100 kDa
(expected intense upper band size, 86 kDa and lower faint band size, 79 kDa). Beta-actin (expected molecular weight/size, 42 kDa) is shown by ladder at
40 kDa. d–fmRNA levels of d Acta2, e Col1a1, and f Col1a2, g hydroxyproline content, hmyoﬁbroblast counts and levels of i CtgfmRNA, j Pai-1mRNA and of the
proposed biomarkers, k Thbs1mRNA, and l CompmRNA.m–o Immunoﬂuorescence analysis including n, o representative immmunoﬂuorescence stainings of P-
STAT3 (left) and total STAT3 (right) at 200-fold and 1000-fold magniﬁcation, respectively, along with theirm quantitative analyses. N≥ 6 mice with 2 technical
replicates per group for all experiments. Results are shown as median± interquartile range (IQR). Horizontal scale bar, 100 μm. Signiﬁcance was determined by
Mann–Whitney test, as compared to vehicle-treated, ﬁbrotic mice, respectively. *P<0.05; **P<0.01***; P<0.001
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control antibodies (Santa Cruz Biotechnology, Heidelberg, Germany) were used as
controls. Counter staining of cell nuclei was performed using DAPI (Santa Cruz
Biotechnology). Stained cells were visualized using a Nikon Eclipse 80i microscope
(Nikon).
For quantiﬁcation, single, spindle-shaped cells in the dermis positive for the
required positive antibody were counted in six randomly chosen high-power ﬁelds
at 200-fold magniﬁcation by two experienced researchers in a blinded manner as
described13.
Integrated density was analyzed using ImageJ Software (NIH, version 1.49).
Confocal microscopy and analysis. Confocal images of tissue sections were
acquired using a Leica SP5 II confocal laser scanning microscope (Leica Micro-
systems, Heidelberg, Germany) with ×63 glycerol-immersion objective and scan-
ning resolution of 512 × 512 pixels, zoom factor 6.4. Image stacks consisting of a
series of images at 1 μm intervals throughout the entire cell nucleus were taken at
randomly selected tissue areas. The images were deconvoluted with the Huygens
deconvolution software (Scientiﬁc Volume Imaging B.V.). The DAPI channels
were then smoothed by convolving with a Gaussian kernel (sigma= 5 pixels) and
nuclei were segmented by automatic global thresholding (using ImageJ’s Otsu
method). Likewise, YY in the XX channel were segmented using automatic Otsu
global thresholding. Afterwards, the ratios of YY between inside and outside of
nuclei were calculated for each image. The entire workﬂow was performed fully
automatically to exclude any bias, by a custom ImageJ macro.
Animal studies. Two different mouse models were employed: bleomycin-induced
skin ﬁbrosis, and ﬁbrosis induced by injections of replication-deﬁcient type 5 ade-
noviruses encoding for a constitutively active TBRI construct52,66. For bleomycin-
induced skin ﬁbrosis, 6-week-old mice received repeated subcutaneous injections of
bleomycin (100 µl) at a concentration of 0.5mg/ml in deﬁned areas of 1 cm2 at the
upper back every other day for 4 weeks. Mice injected with equal volumes of 0.9 %
sodium chloride served as controls. In a subset of experiments, mice were treated with
intraperitoneal injection of c-ABL inhibitor imatinib mesylate (150mg/kg/day) or
SRC inhibitor SU6656 (12mg/kg/day dissolved in 20% DMSO/80% NaCl) or an oral
gavage of JAK2 inhibitor TG101209 (200mg/kg/day) or JNK inhibitor CC-930
(300mg/kg/day, Celgene, New Jersey, USA) for 21 days. Control mice were injected
with bleomycin and with vehicle for the respective individual inhibitors. All inhibitors
were dissolved in 0.9% NaCl unless otherwise mentioned. For TBRact-induced
ﬁbrosis, 4-week-old mice received of 6.67 × 107 pfu/mouse of replication-deﬁcient
type 5 adenoviruses encoding for TBRIact into deﬁned areas of 1 cm2 at the upper
back four times per 2 months. Mice injected with LacZ-expressing viruses served as
controls. To selectively inactivate STAT3 in ﬁbroblasts, mice carrying two conditional
alleles of STAT3 (STAT3ﬂ/ﬂ) were crossbred with col1a2-Cre-ER mice to generate
col1a2-Cre-ER STAT3ﬂ/ﬂ. Cre-mediated recombination was induced by repeated i.p.
injections of tamoxifen over 5 days. Control groups were injected with corn oil. For
pharmacological inhibition of STAT3, we used selective STAT3 inhibitor S3I-201
(10mg/kg/day). All mouse experiments were approved by the governments of Mit-
telfranken and/or Unterfranken.
Histologic analysis. The injected skin areas of all mice were ﬁxed in 4% formalin
and embedded in parafﬁn. Histologic sections were stained with hematoxylin and
eosin for the determination of dermal thickness. The dermal and hypodermal
thickness was visualized using a Nikon Eclipse 80i microscope (Nikon) and ana-
lyzed at four different sites in each mouse in a blinded manner as described13,65.
For visualization of collagen content, trichome staining was performed (Sigma-
Aldrich). Hydroxyproline content and α-smooth muscle actin positive myoﬁbro-
blasts were analyzed as described previously65,67.
Statistics. All data are presented as median with interquartile range (IQR). Dif-
ferences between the groups were tested for their statistical signiﬁcance by
Mann–Whitney U-test for non-related samples and by the Wilcoxon signed rank
tests for related samples. In a subset of experiments, the mean values of the control
groups were set to 1. All other values were expressed as x-fold changes compared
with the respective controls used as ‘comparison mean values’. P values less than
0.05 were considered signiﬁcant.
Data availability. All data generated or analysed during this study are included in this
published article (and its Supplementary Information ﬁles). Additional supporting
informations are available from the corresponding author on reasonable request.
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